Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Publication/Presentation Date
12-2016
Volume
128
Issue
22
First Page
2122
Last Page
2122
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Fellows and Residents
Document Type
Article
COinS